Double-blind, parallel, randomized pilot study comparing the efficacy and tolerance of cetirizine 10 mg, mequitazine 2 � 5 mg and placebo in the treatment of patients suffering from chronic urticaria: Comparison of suppressive effects on histamine-induced weals and flares

西替利嗪 医学 安慰剂 红斑 不利影响 随机对照试验 双盲 随机化 麻醉 内科学 外科 替代医学 病理
作者
Ahmed M. Abu Shareeah,Mohammed Youssuf,Ilse Deckers,C. Mahieu
出处
期刊:Drug Development Research [Wiley]
卷期号:43 (4): 185-192 被引量:5
标识
DOI:10.1002/(sici)1098-2299(199804)43:4<185::aid-ddr1>3.0.co;2-e
摘要

In a double-blind, randomized, parallel-group study, 29 adult patients suffering from chronic urticaria were treated with either cetirizine 10 mg od (n = 10), mequitazine 5 mg bid (n = 10), or placebo (n = 9) for 3 weeks. Three symptoms (weals, erythema, pruritus) were rated according to severity (none, mild, moderate, severe) by the investigator at each of the four visits (days 1, 3, 14, 21). At each visit the investigator and patients also assessed the patients' general condition using a 5-point scoring system (very bad, bad, moderate, good, very good). On day 21 the global evaluation of efficacy and tolerance was assessed by the investigator and patients on a 4-point scale (excellent, good, moderate, bad). Also, a histamine skin-prick test was performed on days 3, 14, and 21. Evaluation of safety was based on the frequency of patients reporting adverse events as well as the clinical laboratory results. The cetirizine, mequitazine, and placebo groups of patients were comparable at inclusion. Overall compliance with the trial schedule was excellent for all groups. After 3 days of treatment a significant improvement in control of all urticaria symptoms was observed in the cetirizine group. Cetirizine elicited a statistically significant better control of pruritus (P = 0.006) and erythema (P = 0.018) than mequitazine on day 21. A trend in favor of cetirizine vs. mequitazine was also observed regarding control of weals (P = 0.114). Cetirizine clearly and rapidly improved the general condition of the patient as evaluated by both patients and investigator compared to the baseline results. The differences vs. mequitazine as well as vs. placebo were statistically significant on every visit, starting from day 3. After three weeks of treatment, the clinical efficacy results in the cetirizine group were rated by both patients and investigator as excellent or good, which was statistically significantly better than the results obtained in the mequitazine and placebo group (P > 0.05). The histamine skin-prick test results revealed a marked difference for the group treated with cetirizine compared to the two other groups in favor of CTZ. On day 3, cetirizine produced a statistically significant suppression of the weals (98%) and flares (74%), compared to 24% and 3%, respectively, by mequitazine. With respect to the tolerance results, no statistically significant differences were observed between the three groups. The safety profile was similar for all groups. No serious adverse event has been reported during the present study, nor did the treatments induce any clinically significant abnormal changes in the laboratory tests. It can be concluded from the present study that the effect of cetirizine was statistically and clinically significantly superior to that of mequitazine. On the other hand, of all parameters studied there were no marked differences between the patients of the mequitazine group and the patients of the placebo group. Drug Dev. Res. 43:185–192, 1998. © 1998 Wiley-Liss, Inc.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
3333333333完成签到,获得积分10
1秒前
1秒前
秋风的应助被雪落采纳,获得10
1秒前
1秒前
十三完成签到,获得积分10
2秒前
2秒前
852的应助被Future采纳,获得30
3秒前
王青奎发布了新的文献求助10
3秒前
4秒前
Plateau发布了新的文献求助10
4秒前
华仔的应助被Fred_Whu采纳,获得10
4秒前
4秒前
kevin1018发布了新的文献求助10
5秒前
hxzcell发布了新的文献求助10
6秒前
wudi完成签到,获得积分10
6秒前
GZU老僵尸发布了新的文献求助10
6秒前
有梦想的咸鱼完成签到,获得积分10
6秒前
烟花的应助被zhazha采纳,获得10
7秒前
张不大发布了新的文献求助10
7秒前
上官若男的应助被小库里2025采纳,获得10
7秒前
qducly2026的应助被朱玉采纳,获得30
7秒前
7秒前
Owen的应助被李RP采纳,获得10
7秒前
求助文献发布了新的文献求助20
7秒前
海格完成签到,获得积分10
8秒前
MHR发布了新的文献求助10
9秒前
9秒前
10秒前
10秒前
夏伊完成签到,获得积分10
10秒前
wbq完成签到,获得积分10
11秒前
赘婿的应助被结草衔环采纳,获得10
11秒前
11秒前
嘚儿塔发布了新的文献求助10
11秒前
恋恋青葡萄完成签到,获得积分10
12秒前
假发君完成签到,获得积分10
12秒前
积极剑通发布了新的文献求助10
12秒前
思源的应助被1112233采纳,获得10
13秒前
充电宝的应助被Fred_Whu采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8156628
求助须知:如何正确求助?哪些是违规求助? 9552750
关于积分的说明 21711279
捐赠科研通 7745718
什么是DOI,文献DOI怎么找? 3426593
关于科研通互助平台的介绍 2551401
邀请新用户注册赠送积分活动 2470435